A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
Status:
Not yet recruiting
Trial end date:
2027-03-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Nipocalimab versus
placebo in participants with active idiopathic inflammatory myopathies (IIM).